Even though recent clinical trials have identified novel targets such as menin inhibitor in 11q23/KMT2A‐ rearranged AML to impair leukemia growth and proliferation, comprehensive genome analyses provide a more thorough biological understanding for 11q23/KMT2A‐rearranged AML, which contributes to the exploration of targeted therapy.10, 11. This evidence concerns the gene KMT2A and acute myeloid leukemia.